New diabetes drug shows promise in 12-Week trial
NCT ID NCT00998881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new diabetes medicine called MP-513 (Teneligliptin) in 203 Japanese adults with type 2 diabetes. The goal was to see if the drug safely lowers blood sugar levels over 12 weeks. Participants took either the drug or a placebo pill, and researchers measured changes in HbA1c (a long-term blood sugar marker) and fasting glucose. This is a disease-control study, not a cure, as diabetes requires ongoing management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Sapporo, Hokkaido, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?
- A pill for diabetes? new oral drug aims to rival injections